Pharmacy World & Science

, Volume 30, Issue 6, pp 876–883 | Cite as

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

  • Kazeem B. YusuffEmail author
  • Olubunmi Obe
  • Bonatson Y. Joseph
Research Article


Objective To describe the pattern of anti-diabetic drug prescribing; ascertain the level of glycemic control, adherence with prescribed anti-diabetic medications, and diabetes self management practices among patients with type-2 diabetes in a tertiary care setting in Nigeria. Setting University College Hospital (UCH); a 900 bed teaching hospital with medical residents located in Ibadan, southwestern Nigeria. Method The study consisted of two phases. A cross-sectional review of randomly selected 200 case notes of type 2 diabetic patients that attended the Endocrinology clinic over 3 month; and crosssectional interviews, with a pre-tested Adherence and Self-Management Monitoring Tool (ASMMT), of 200 consecutive patients that presented their drug prescriptions at the satellite pharmacy unit over a 4 week period at a 900-bed teaching hospital located in Ibadan, South-Western Nigeria. Results Oral Hypoglycemic Agents (OHA) were prescribed for 86% (171) of cohorts while insulin and OHA was prescribed in 14% (29). About 70.8% (121) of patients on OHA were on combination therapy. The most frequently prescribed OHA combination was glibenclamide and metformin (95.8%). Glibenclamide was prescribed as twice daily regimen in 69% of cohorts. The most frequently documented side effect was hypoglycemia (60.3%). Only 44% (88) of cohorts had adequate glycemic control; of these, 93% (82) were adjudged adherent with prescribed anti-diabetic drugs. Interviews with the structured ASMMT revealed that 59% of patients were non-adherent with the previous anti-diabetic drugs due to lack of finance (51.7%); side effects (34.5%); perceived inefficacy of prescribed anti-diabetic drugs leading to self-medication with local herbs (13.8%). Only 20% of non-adherent patients claimed disclosure to physicians during consultation. The identified factors for non-disclosure were lack of privacy during consultation (58%); and short consultation time (42%). The knowledge and practice of critical components of diabetes self-management behaviours were generally low among the cohort studied. However, it was significantly higher among patient judged adherent with their prescribed anti-diabetic medications (P < 0.05). Conclusion Majority of patients with type 2 diabetes in an ambulatory tertiary care setting in Nigeria are managed with OHA combinations, mainly glibenclamide and metformin. While the current prescribing strategy achieved glycemic control in about one third of patients, majority are still not meeting the recommended blood glucose targets due to poor adherence with prescribed drug regimen, and poor knowledge and practice of successful self-management.


Adherence Anti-glycemic drugs Blood glucose Diabetes mellitus type 2 Nigeria Prescribing Self-management 



We acknowledge the guidance and support of Prof. Fola Tayo, Department of Clinical Pharmacy & Biopharmacy, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria.



Conflicts of Interest



  1. 1.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–31.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organisation. Diabetes mellitus fact sheet, Number 238. 2002. Cited 13 Aug 2006.
  3. 3.
    Haffner SM, Lehto S, Ronnemma T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Russell RB, Valiyeva E, Roman SH, Pogach LM, Suh D, Safford MM. Hospitalization, nursing home admission and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Beckman JA, Creager MQ, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J. 2006;332:73–8.CrossRefGoogle Scholar
  7. 7.
    Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.PubMedCrossRefGoogle Scholar
  8. 8.
    American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999;22:S27–31.CrossRefGoogle Scholar
  9. 9.
    Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15.CrossRefGoogle Scholar
  10. 10.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  11. 11.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.CrossRefGoogle Scholar
  12. 12.
    Cohen FJ, Conklin JE, Neslusan CA, Song X. Recent antihyperglyceamic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Turner RC, Cull CA, Fright V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA. 1999;281:2005–12.Google Scholar
  14. 14.
    Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.PubMedGoogle Scholar
  15. 15.
    Chuang LM, Tsai ST, Huang BY, Tai TY; Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia- a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabetes Med. 2002;19:978–85.Google Scholar
  16. 16.
    Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Wong JS, Rahimah N. Glycemic control of diabetic patients in an urban primary health care setting in Sarawak: the Tanah Putch Health Centre experience. Med J Malaysia. 2004;59(3):411–7.PubMedGoogle Scholar
  18. 18.
    El-Kebbi IM, Gallina DL, Ziemer DC, et al. Diabetes in urban African-Americans. VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care. 1998;21(4):501–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Ndububa DA, Erhabor GE. Diabetic mortalities in Ilesa, Nigeria: a retrospective study. Cent Afr J Med. 1994;40(10):28–9.Google Scholar
  20. 20.
    Puepet FH, Agaba EI, Chuhwak EK. Some metabolic abnormalities in type 2 diabetic patients in Jos, north central Nigeria. Niger J Med. 2003;12(4):193–7.PubMedGoogle Scholar
  21. 21.
    Alebiosu CO. Clinical diabetic neuropathy in a tropical African population. West Afr J Med. 2003;22(2):152–5.PubMedGoogle Scholar
  22. 22.
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27:2444–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Sullivan PW, Morrato EH, Ghushehyan V, et al. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000–2002. Diabetes Care. 2005;28:1599–603.PubMedCrossRefGoogle Scholar
  25. 25.
    American Diabetes Association (ADA). Standard of medical care in diabetes. Diabetes Care. 2005;28:S10–20.CrossRefGoogle Scholar
  26. 26.
    Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol. 2004;151:T3–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–20.PubMedCrossRefGoogle Scholar
  28. 28.
    British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, March 2005. London: BMJ Publishing Group and Royal Pharmaceutical Society of Great Britain; 2005.Google Scholar
  29. 29.
    American Society of Health-System Pharmacists/American Hospital Formulary Services (ASHP/AHFS). AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2002.Google Scholar
  30. 30.
    Wan Mohamad WB, Tun Fizi A, Ismail RB, Mafauzy M. Efficacy and safety of Single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res. 2000;49(2):93–9.CrossRefGoogle Scholar
  31. 31.
    Marre M, Howlett H, Lehert P, Allavoine T. Improved glycemic control with metformin–glibenclamide combined tablet therapy in type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in amanged care organization: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther. 2002;24(3):460–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Erasmus RT, Blanco B, Okesina AB, Gqweta Z, Matsha T. Assessment of glycemic control in stable type 2 black south African diabetics attending a peri-urban clinic. Postgrad Med J. 1999;75:603–6.PubMedGoogle Scholar
  34. 34.
    Kolawole BA, Adegbenro C, Ayoola ZO, Opebiyi B. Diabetes mellitus related treatment goals: awareness and attainment in the Ife-Ijesha zone of south-western Nigeria. Afr J Med Med Sci. 2005;34(4):389–94.Google Scholar
  35. 35.
    United Nation Development Programme (UNDP). Eye of the needle—Nigeria 2000. New York, USA: Human Development Reports; 2000.Google Scholar
  36. 36.
    Seltzer HS. Drug induced hypoglycemia. Endocrinol Metab Clin North Am. 1989;18:163–83.PubMedGoogle Scholar
  37. 37.
    Talabi OA. A questionnaire survey of senior house officers/registrars response to their training at University College Hospital, Ibadan. West Afr J Med. 2003;22(2):108–11.Google Scholar
  38. 38.
    Ndom RJE, Makanjuola AB. Perceived stress factors among resident doctors in a Nigerian teaching hospital. West Afr J Med. 2004;23(3):78–81.Google Scholar
  39. 39.
    Ajayi IO, Olumide EA, Oyediran O. Patient satisfaction with the services provided at a general outpatient clinic, Ibadan, Oyo state, Nigeria. Afr J Med Med Sci. 2005;34:133–40.PubMedGoogle Scholar
  40. 40.
    Glasgow RE, Strycker LA, Hampson SE, Ruggiero L. Personal model beliefs and social-environmental barriers related to diabetes self-management. Diabetes Care. 1997;20:556–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Day JL. Diabetic patients education: determinants of success. Diabetes Metab Res Rev. 2000;16(Supl 1):S70–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Campbell RK. Role of the pharmacists in diabetes management. Am J Health Syst Pharm. 2002;59(9):18–21.Google Scholar
  43. 43.
    Acheampong JW, Boateng KA, Eghan BA, Story P, Parry EHO, Tomlinson S. The impact of diabetes nurses in the Komfo Anokye Teaching Hospital, Ghana. Diabetes Int. 2000;10:81–3.Google Scholar
  44. 44.
    Berthoet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in management of hypertension. J Clin Hypertens. 2000;2:210–4.Google Scholar
  45. 45.
    Fodor GJ, Kotrec M, BacsKai K, et al. Is interview a reliable method to verify compliance with antihypertensive therapy? An international central-European study. J Hum Hypertens. 2005;23:1261–6.Google Scholar
  46. 46.
    Yusuff KB, Alabi A. Assessing patient adherence to anti-hypertensive drug therapy: can a structured pharmacist-conducted interview separate the wheat from the chaff? Int J Pharm Pract. 2007;15:295–300.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Kazeem B. Yusuff
    • 1
    Email author
  • Olubunmi Obe
    • 1
  • Bonatson Y. Joseph
    • 2
  1. 1.Department of Clinical Pharmacy & Pharmacy Administration, Faculty of PharmacyUniversity of IbadanIbadanNigeria
  2. 2.Department of Clinical Pharmacy & Biopharmacy, Faculty of PharmacyUniversity of LagosLagosNigeria

Personalised recommendations